4basebio AG: 4basebio announces share capital reduction by way of reverse stock split

4basebio sets out details of the Spin-off of the DNA business

Heidelberg (pta062/05.10.2020/21:39 UTC+2) The Management Board and the Supervisory Board of 4basebio AG have today decided to convene an extraordinary general meeting in the form of a virtual general meeting for 3 November 2020 and to propose to this meeting, among other things, an ordinary capital reduction in accordance with Secs. 222 ff. German Stock Corporation Act by way of consolidation of shares of the Company. The share capital of 4basebio AG is to be reduced from EUR 51,733,386 to EUR 5,748,154. Accordingly, the issued shares of 4basebio AG are to be consolidated at a ratio of 9 to 1. Nine existing registered no-par value shares would thus become one new registered no-par value share with an arithmetic share in the share capital of EUR 1.00.

The capital reduction shall only be implemented after the completion of the Spin-off of the DNA business of the Company announced in the ad hoc release of August 17, 2020. As part of the Spin-off, the shareholders of 4basebio AG will receive one share in 4basebio SE (currently still trading under the name Atrium 180 European VV SE) for each six shares held in 4basebio AG (prior to the capital reduction). When the Spin-off becomes effective, the shareholders of 4basebio AG will directly hold 70% of the shares in 4basebio SE, while a minority interest of 30% will remain with 4basebio AG. 4basebio SE will offer shareholders of 4basebio AG, who have their objection recorded with regard to the resolution of the shareholders' meeting on the approval of the Spin-off, to acquire the shares in 4basebio SE granted within the framework of the Spin-off for EUR 1.30 per share in accordance with Sec. 29 para. 2 of the German Transformation Act (UmwG). A registration of the new shares of 4basebio SE in the securities accounts of the shareholders of 4basebio AG is still aimed for to occur before the end of December 2020. However, it cannot be ruled out that the corresponding listing on the London Stock Exchange (Alternative Investment Market segment) will only take place in 2021.

*** end of ad hoc announcement ***

For further information, please contact:

4basebio AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@4basebio.com
Investors' information: investors.4basebio.com

(end)

Emitter:	4basebio AG Waldhofer Str. 102 69123 Heidelberg Germany
Contact Person:	Robert Mayer
Phone:	+49 171 3876540
E-Mail:	robert.mayer@4basebio.com
Website:	investors.4basebio.com
ISIN(s):	DE000A2YN801 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate